The prevalence of diagnosed and undiagnosed diabetes in the US is progressively increasing from 7.8% in 2007, 14.5% in 2010 and expected to rise to between 24.7% and 32.8% in 2050. Diabetic nephropathy (DN) remains an important and unresolved complication of diabetes. It has become evident that endothelial cell dysfunction is a central pathophysiological mechanism contributing to diabetes and DN. Growing evidence from our work and others suggests that dramatic alterations in arginine metabolism occur during endothelial injury in response to changes in the activity and/or expression of nitric oxide synthases (NOS) and/or arginases. Arginase-2 is constitutively expressed and regulated in the kidney, but not arginase-1. Our recent work demonstrates that arginase inhibition mediates renal tissue protection in DN via an eNOS-dependent mechanism. Therefore, we hypothesize that a selective inhibitor of arginase-2 will prove to be an optimal drug for protecting against diabetic nephropathy. Such a selective agent would be a valuable adjunct to blood glucose control in mitigating this important unmet medical need.
Aim 1 : Modify our novel lead compound ASR-133 to render it more arginase-2 selective and potent.
Aim 2 : In vitro assessment of pharmacotherapeutic potential of arginase inhibitors. Identification of an arginase-2 selective inhibitor would provide a potentially important pre-therapeutic lead for the treatment of diabetic renal complications and may provide a new therapeutic approach to the management of DN.
Currently, the only effective approaches to reduce the progression of diabetic nephropathy are to control the blood glucose and blood pressure levels. Our current hypothesis is that the selective inhibition of arginase-2 will serve to protect the kidney from diabetic nephropathy;however, no arginase-2 specific inhibitors currently exist. Therefore, the current study will develop arginase-2 selective inhibitors to provide a new therapeutic approach to the development and progression of diabetic nephropathy.
| Morris Jr, Sidney M; You, Hanning; Gao, Ting et al. (2017) Distinct roles of arginases 1 and 2 in diabetic nephropathy. Am J Physiol Renal Physiol 313:F899-F905 |
| You, Hanning; Gao, Ting; Raup-Konsavage, Wesley M et al. (2017) Podocyte-specific chemokine (C-C motif) receptor 2 overexpression mediates diabetic renal injury in mice. Kidney Int 91:671-682 |
| Raup-Konsavage, Wesley M; Gao, Ting; Cooper, Timothy K et al. (2017) Arginase-2 mediates renal ischemia-reperfusion injury. Am J Physiol Renal Physiol 313:F522-F534 |
| You, Hanning; Gao, Ting; Cooper, Timothy K et al. (2015) Arginase inhibition: a new treatment for preventing progression of established diabetic nephropathy. Am J Physiol Renal Physiol 309:F447-55 |
| Awad, Alaa S; You, Hanning; Gao, Ting et al. (2015) Delayed Treatment with a Small Pigment Epithelium Derived Factor (PEDF) Peptide Prevents the Progression of Diabetic Renal Injury. PLoS One 10:e0133777 |
| Sun, Yuan-Wan; El-Bayoumy, Karam; Aliaga, Cesar et al. (2015) Tissue Distribution, Excretion and Pharmacokinetics of the Environmental Pollutant Dibenzo[def,p]chrysene in Mice. Chem Res Toxicol 28:1427-33 |
| Awad, Alaa S; You, Hanning; Gao, Ting et al. (2015) Macrophage-derived tumor necrosis factor-? mediates diabetic renal injury. Kidney Int 88:722-33 |
| You, Hanning; Gao, Ting; Cooper, Timothy K et al. (2014) Diabetic nephropathy is resistant to oral L-arginine or L-citrulline supplementation. Am J Physiol Renal Physiol 307:F1292-301 |
| You, Hanning; Gao, Ting; Cooper, Timothy K et al. (2013) Arginase inhibition mediates renal tissue protection in diabetic nephropathy by a nitric oxide synthase 3-dependent mechanism. Kidney Int 84:1189-97 |
| You, Hanning; Gao, Ting; Cooper, Timothy K et al. (2013) Macrophages directly mediate diabetic renal injury. Am J Physiol Renal Physiol 305:F1719-27 |
Showing the most recent 10 out of 13 publications
